PT-141 (Bremelanotide) Pregnancy & Lactation Safety: What the Evidence Actually Shows

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. It acts centrally, not genitally, which is what separates it mechanistically from phosphodiesterase inhibitors and topical treatments.

Melanocortin Receptor Pharmacology

The drug binds with varying affinity to melanocortin receptors MC1R, MC3R, and MC4R. MC4R activation in the hypothalamus is thought to drive the pro-sexual effect by modulating dopaminergic and serotonergic pathways that govern desire [1]. This central mechanism means the drug crosses or acts at the blood-brain barrier, a pharmacokinetic property that carries reproductive implications discussed below.

The FDA-approved prescribing information for Vyleesi details receptor binding affinities and notes that the melanocortin system has broad physiologic roles beyond sexual function, including energy balance, inflammation, and pigmentation [2]. MC1R activation in particular accounts for the transient hyperpigmentation (focal melanosis) seen in roughly 1% of users on long-term administration.

Pharmacokinetics Relevant to Reproductive Risk

After a 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration (Cmax) within about 1 hour. Its volume of distribution is approximately 40 L, indicating moderate tissue penetration [2]. The drug is metabolized by hydrolysis of the amide bonds, not by cytochrome P450 enzymes, which limits drug-drug interactions but does not reduce reproductive exposure risk.

Protein binding runs at roughly 21%, leaving a sizeable free fraction. The terminal half-life is approximately 2.7 hours [2]. The relatively short half-life does not eliminate the window of embryonic exposure if the drug is taken before a pregnancy is recognized, since most women do not know they are pregnant until 4 to 6 weeks of gestation.

FDA Pregnancy Classification and Label Requirements

The Vyleesi prescribing information carries an explicit contraindication for use in pregnancy. This is not a precautionary warning, it is a hard contraindication backed by animal reproductive toxicology [2].

What the Label Actually States

The FDA label states: "Vyleesi is contraindicated during pregnancy. Discontinue Vyleesi if pregnancy is confirmed" [2]. The label also requires that a pregnancy test be performed before the drug is prescribed, and the prescriber information recommends monthly pregnancy testing during use for women who are not using reliable contraception.

This language is notable because most drugs with reproductive concerns carry a Category X analog warning (under the legacy system) or a "contraindicated" pregnancy subsection under the newer Pregnancy and Lactation Labeling Rule (PLLR). Bremelanotide falls into the latter framework, with the label updated to PLLR format after the 2015 rule took effect [3].

Comparing Pregnancy Risk Language Across Sexual Health Drugs

Among FDA-approved female sexual dysfunction drugs, both bremelanotide and flibanserin carry pregnancy contraindications. Flibanserin's label similarly prohibits use in pregnancy, supported by animal data showing fetal harm [4]. The parallel is clinically useful: both drugs act centrally on neurotransmitter systems, and both carry signals of embryonic or fetal toxicity in preclinical models.

Animal Reproductive Toxicology: What the Studies Show

No controlled human studies exist on bremelanotide in pregnancy. The reproductive risk framework depends entirely on animal data, and those data are concerning enough to justify the contraindication.

Rat and Rabbit Embryo-Fetal Development Studies

In embryo-fetal development studies conducted by Palatin Technologies and summarized in the FDA prescribing information, bremelanotide administered to pregnant rats at doses producing exposures 16 times the human area-under-the-curve (AUC) at the 1.75 mg clinical dose produced fetal malformations and increased post-implantation loss [2]. Rabbit studies at exposures approximately 7 times the human AUC showed similar embryolethality.

These multiples sound large, but standard FDA guidance (ICH S5) requires reproductive safety margins of at least 10-fold over the human AUC to consider a drug "adequately safe" in preclinical testing [5]. Bremelanotide does not meet that threshold in rabbits. The rat threshold is exceeded, but fetal harm still occurred, which is why the label takes the position it does.

Melanocortin System in Early Development

The melanocortin system is not merely a sexual-function pathway. MC3R and MC4R are expressed in the developing embryo and in placental tissue [6]. Exogenous agonism of these receptors during organogenesis (days 18 to 55 post-conception in humans) may interfere with normal developmental signaling. A 2016 review in the Journal of Endocrinology documented that hypothalamic melanocortin circuits are active during fetal development and play a role in energy sensing and neuronal differentiation [6].

This mechanistic basis gives biological plausibility to the animal findings. It is not simply a matter of non-specific toxicity at high doses, there is a receptor-level reason to expect that exogenous MC4R agonism during sensitive developmental windows could disrupt normal fetal programming.

Postnatal Development Data

Rat pup studies showed reduced survival and altered developmental milestones when dams received bremelanotide during the perinatal and lactation periods in preclinical work summarized in the label [2]. These pup effects may reflect direct milk transfer of the drug or indirect effects on maternal behavior mediated through central MC4R modulation. Either mechanism is clinically relevant when considering postpartum use.

Bremelanotide and Breastfeeding: Parsing the Evidence Gap

No published human data describe bremelanotide concentrations in breast milk, infant plasma, or infant outcomes following maternal use. This is not unusual for a drug approved for premenopausal women and used on-demand rather than daily, but the absence of data does not equal absence of risk.

Pharmacokinetic Predictors of Milk Transfer

Three pharmacokinetic properties determine whether a drug concentrates in breast milk: molecular weight, protein binding, and lipophilicity (logP). Bremelanotide has a molecular weight of approximately 1,025 Daltons, which is large enough that passive diffusion into milk would be limited [7]. However, protein binding is only 21%, leaving a meaningful free fraction. The drug's logP is not publicly reported in standard databases, but its cyclic peptide structure and central nervous system activity suggest sufficient lipophilicity to partition into milk to some degree.

LactMed, the National Institutes of Health lactation database, currently lists bremelanotide with a summary of "no data" for maternal milk levels and concludes that use during breastfeeding should be avoided until human data are available [7].

Infant Risk Considerations

If bremelanotide does transfer into milk, the primary concern for a nursing infant is MC4R agonism during a period of active hypothalamic development. Neonatal MC4R activity regulates energy intake, and disruption of this signaling in the first months of life may carry metabolic consequences that are difficult to detect clinically in real time [6].

A secondary concern is the drug's vasoconstrictor properties. Bremelanotide transiently increases blood pressure by approximately 2 to 4 mmHg systolic in adults [2]. In a neonate with immature vascular regulatory mechanisms, even trace systemic exposure to a vasoactive peptide warrants caution.

Clinical Recommendation on Lactation

Given the lack of human lactation data, the animal signals of pup toxicity, and the plausible pharmacokinetic pathway for milk transfer, clinicians should advise patients to avoid bremelanotide while breastfeeding. If a patient with postpartum HSDD requests treatment, non-pharmacologic interventions (psychosexual therapy, couples counseling, hormonal evaluation for hypoestrogenism) should be tried first. For women who have weaned, the standard premenopausal RECONNECT criteria apply once a pregnancy test is confirmed negative.

The RECONNECT Trials: Who Was (and Was Not) Studied

The two Phase 3 RECONNECT trials (combined N=1,267 premenopausal women with generalized acquired HSDD) published in Obstetrics and Gynecology in 2019 are the clinical foundation for bremelanotide's approval [1]. Both trials excluded women who were pregnant, planning to become pregnant, or breastfeeding. This is standard for HSDD trials, but it means the entire efficacy and safety database for bremelanotide comes from women actively avoiding pregnancy.

Efficacy Results in the Eligible Population

Across both RECONNECT trials, women randomized to bremelanotide 1.75 mg showed statistically significant improvements on the Female Sexual Function Index desire domain and on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score compared to placebo [1]. The FSDS-DAO improvement (the co-primary endpoint) was approximately 0.3 points greater than placebo, P<0.001 for the combined dataset. Nausea was the most common adverse event, occurring in about 40% of bremelanotide users versus 1% of placebo users.

Enrollment Criteria That Excluded Reproductive-Age Risk Groups

RECONNECT required participants to use reliable contraception throughout the trial [1]. This protocol requirement reflects the pre-existing animal safety signal. Investigators knew from IND-stage toxicology that a pregnancy contraindication would be necessary, and trial design accommodated that by mandating contraception. The result is that no within-trial pregnancy exposures were captured, and no accidental-pregnancy safety data are available from the key program.

A Decision Framework for Premenopausal Women with HSDD Who Want to Conceive

Clinicians encounter a specific and underaddressed scenario: a premenopausal woman with diagnosed HSDD who is currently using bremelanotide and wants to start trying to conceive. The FDA label gives clear instruction to discontinue before attempting conception, but it does not specify a washout duration.

Given the 2.7-hour terminal half-life, bremelanotide is pharmacokinetically cleared within approximately 5 to 6 half-lives, meaning plasma levels fall below quantifiable limits within roughly 16 hours of the last dose [2]. On that basis, a single missed dose before an unprotected cycle is not a pharmacokinetic catastrophe. The more important clinical message is that women should stop the drug before they discontinue contraception, not after they get a positive pregnancy test, because organogenesis is already underway by the time home pregnancy tests turn positive at 4 weeks of gestation.

A reasonable clinical sequence for women planning conception:

1. Stop bremelanotide at least one full menstrual cycle before discontinuing contraception. This builds in a margin beyond the pharmacokinetic washout.
2. Address HSDD through psychosexual therapy during the conception-attempt period. Evidence from randomized trials supports the efficacy of mindfulness-based sex therapy for HSDD in premenopausal women [8].
3. Recheck HSDD symptoms postpartum after weaning. If symptoms persist and breastfeeding has ended, confirm negative pregnancy test and restart bremelanotide if clinically appropriate.

Hypoactive Sexual Desire Disorder: Prevalence and Context

HSDD affects approximately 8% to 10% of premenopausal women in the United States when defined by the DSM-5 criteria requiring associated personal distress [9]. The condition is not a side-effect of aging alone. It occurs across the reproductive lifespan and is specifically the indication for which bremelanotide is approved.

Why Premenopausal Women Are the Target Population

The RECONNECT trials enrolled exclusively premenopausal women, ages 22 to 55, because HSDD in postmenopausal women has a substantial estrogenic component that is addressed differently (with hormone therapy) [1]. Premenopausal HSDD is more likely to reflect central neurotransmitter dysregulation, which is why a centrally acting melanocortin agonist has mechanistic relevance in this group.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that HSDD in premenopausal women should be evaluated for comorbid depression, relationship factors, and hormonal contributors before pharmacotherapy is initiated [10]. Bremelanotide is positioned as a second-line option after these evaluations are complete.

HSDD During Pregnancy and the Postpartum Period

Desire often changes substantially during pregnancy and the postpartum period for hormonal, psychological, and relational reasons. A 2021 cohort study in the Journal of Sexual Medicine (N=832 postpartum women) found that 43% reported low sexual desire at 3 months postpartum, with hormonal suppression from breastfeeding as a primary driver [11]. These women would not be candidates for bremelanotide regardless of whether a safety signal existed, because breastfeeding is an exclusion and postpartum women are not the approved population.

Blood Pressure and Cardiovascular Signals: Added Relevance in Pregnancy

Bremelanotide carries a label warning about transient blood pressure increases. After a single 1.75 mg dose, systolic blood pressure rises a mean of approximately 2 to 4 mmHg and diastolic approximately 1 to 2 mmHg, peaking at 2 hours post-dose and resolving within 12 hours [2]. In non-pregnant women, this is modest and clinically manageable.

In pregnancy, any vasoconstrictor signal takes on different weight. Hypertensive disorders of pregnancy affect roughly 10% of pregnancies in the United States and are the second leading cause of maternal mortality [12]. The pressor effect of bremelanotide, while transient and small in healthy adults, has not been studied against the altered vascular physiology of pregnancy, including the high-output, low-resistance state of the second trimester and the heightened renin-angiotensin-aldosterone activity of the third trimester.

This cardiovascular uncertainty adds a second, independent reason to keep bremelanotide away from pregnant women, beyond the embryotoxicity data.

Regulatory and Prescribing Safeguards

The FDA required Palatin Technologies to implement a Risk Evaluation and Mitigation Strategy (REMS) for bremelanotide at approval, though the REMS was subsequently modified. The current prescribing framework requires a negative pregnancy test before initiation and recommends monthly testing for women not on reliable contraception [2].

The American College of Obstetricians and Gynecologists (ACOG) has not issued a separate committee opinion specifically on bremelanotide, but their 2021 practice bulletin on female sexual dysfunction references FDA-approved pharmacotherapies for HSDD and emphasizes the importance of contraception counseling when these agents are prescribed to women of reproductive age [13].

Off-Label Use and Compounded PT-141

A significant proportion of PT-141 use in the United States occurs outside the FDA-approved Vyleesi framework, through compounding pharmacies that supply the peptide for subcutaneous injection or intranasal use. Compounded bremelanotide carries none of the REMS safeguards, no mandatory pregnancy testing requirement, and no quality-control oversight equivalent to the approved product. Women obtaining compounded PT-141 may not receive the same pregnancy-risk counseling that is built into the Vyleesi prescribing pathway [14].

The FDA has issued guidance warning against compounded versions of FDA-approved drugs when the approved product is available, specifically because compounding bypasses the safety labeling infrastructure [14]. For bremelanotide, this matters most in the pregnancy context, where the contraindication warning and mandated pregnancy testing are the primary safeguards in practice.

Counseling Patients: Key Points for the Clinical Encounter

Patients asking about PT-141 and pregnancy typically fall into three groups: those currently using bremelanotide who want to conceive, those who had an unintentional exposure before a positive pregnancy test, and those who are postpartum and want to know when use can safely resume.

For Patients Planning Conception

Stop bremelanotide before stopping contraception. Given the short half-life, pharmacokinetic risk from the drug itself clears within 24 hours, but the animal embryotoxicity signal makes it prudent to have a full cycle off the drug before conception attempts begin. Address underlying HSDD with psychosexual therapy during the transition period.

For Patients with Unintentional First-Trimester Exposure

No human case series or registry data exist to quantify the actual risk to a human embryo from bremelanotide exposure in the first weeks of pregnancy. The animal data show harm at supratherapeutic exposures, but the rabbit AUC multiple of 7-fold is close enough to the clinical range to be a real concern. Patients with confirmed first-trimester exposure should be referred for obstetric counseling and offered standard anatomic ultrasound at 18 to 20 weeks. The exposure should be reported to the Vyleesi pregnancy exposure registry (1-800-FDA-1088) so that prospective human data can be accumulated [2].

For Postpartum Patients Who Have Weaned

Once breastfeeding has ended and a negative pregnancy test is confirmed, the standard RECONNECT eligibility criteria apply. Confirm that the HSDD diagnosis still meets DSM-5 criteria with associated distress, evaluate for postpartum depression as a comorbid driver (since HSDD and depression frequently co-occur), and prescribe according to the standard 1.75 mg subcutaneous protocol [1].